Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Key takeaways of recent quarter & conference call highlights
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Subscribe To Our Newsletter & Stay Updated
